William N. Harwin

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

Jean‐Marc Nabholtz, Aman U. Buzdar, Michaël Pollak et al. · Journal of Clinical Oncology · 2000 · 996 citations

Pharmacy, Oncology, Pharmacotherapy +15

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

Denise A. Yardley, Edward Arrowsmith, Brooke Daniel et al. · Breast Cancer Research and Treatment · 2017 · 27 citations

Medicine, Oncology, Pharmacology +14

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

Denise A. Yardley, Linda D. Bosserman, Joyce O’Shaughnessy et al. · Breast Cancer Research and Treatment · 2015 · 22 citations

Medicine, Oncology, Pharmacology +17

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,

Ian W. Flinn, William N. Harwin, Ines Macias‐Perez et al. · Blood · 2011 · 21 citations

Medicine, Geriatric Medicine, Oncology +13

Low doses of prophylactic cranial irradiation effective in limited stage small cell carcinoma of the lung

James H. Rubenstein, Daniel E. Dosoretz, Michael J. Katin et al. · International Journal of Radiation Oncology*Biology*Physics · 1995 · 20 citations · Full text

Medicine, Oncology, Radiation Oncology +15